Bristol Myers Squibb was among the participants in cellular therapy developer Clade Therapeutics' series A round, with the proceeds to go to platform development.
US-based stem cell medicine developer Clade Therapeutics received $87m in series A funding yesterday from investors including pharmaceutical firm Bristol Myers Squibb.
Life science-focused investment firm Syncona led the round, which also featured non-profit organisation Emerson Collective and LifeSci Venture Partners, the venture capital arm of healthcare advisory boutique LifeSci Partners.
Founded in 2020, Clade is working on cell transplantation-based therapies using technology which masks human pluripotent stem cells and their adult derivatives. It will channel the funding into further…
